About the CPD Course
This is the fifth module of an eLearning course which features 6 interactive modules, covering a full range of topics within non-muscle invasive bladder cancer. When you have completed this module, you should be able to, Outline key information that patients should receive about intravesical Mitomycin C (MMC) and intravesical Bacillus Calmette-Guérin, (BCG) for NMIBC, Describe the most common side effects of these two agents, Name some steps that can help patients manage side effects and complete their treatment, Describe the contraindications for MMC and BCG intravesical therapies, Describe precautions to consider for patients receiving these treatments.
Receive more information
CPD Provider
CPD Subsectors
Health & Wellbeing
Medical
Pharmaceutical
Scientific Organisations
Scientific Research